Prellis uses an in vitro platform to rapidly generate fully human antibodies with unprecedented diversity which stem directly from human donor immune repertoires. We are seeking (i) 1-2 strategic partnerships for working on target discovery and platform development use cases as well as (ii) broadly for partners to in-license our preclinical portfolio of multispecific antibodies in I&I, oncology and obesity.